In recent years, immune checkpoint blockade (ICB) therapy has caused a paradigm shift in cancer immunotherapy; it primarily inhibits various checkpoints that control host T cell activity by regulating the immune checkpoint interactions, PD-1/PD-L1 and CTLA-4/CD80. The gene discussed is PDCD1; the disease is cancer.